MX2019003288A - Proteínas de mycobacterium tuberculosis en pruebas diagnósticas y dispositivos para la detección y diagnóstico de la tuberculosis. - Google Patents

Proteínas de mycobacterium tuberculosis en pruebas diagnósticas y dispositivos para la detección y diagnóstico de la tuberculosis.

Info

Publication number
MX2019003288A
MX2019003288A MX2019003288A MX2019003288A MX2019003288A MX 2019003288 A MX2019003288 A MX 2019003288A MX 2019003288 A MX2019003288 A MX 2019003288A MX 2019003288 A MX2019003288 A MX 2019003288A MX 2019003288 A MX2019003288 A MX 2019003288A
Authority
MX
Mexico
Prior art keywords
tuberculosis
diagnosis
devices
mycobacterium tuberculosis
diagnostic assays
Prior art date
Application number
MX2019003288A
Other languages
English (en)
Inventor
T Nguyen Hiep-Hoa
Original Assignee
Pace Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pace Diagnostics Inc filed Critical Pace Diagnostics Inc
Publication of MX2019003288A publication Critical patent/MX2019003288A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/538—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona un método para detectar los anticuerpos en una muestra proveniente de un sujeto, en donde los anticuerpos se unen a epítopes mediante antígenos de Mycobacterium tuberculosis, que comprende poner en contacto la muestra con dos o más polipéptidos aislados o fragmentos antigénicos o variantes de los mismos, en donde los polipéptidos comprenden polipéptidos seleccionados del grupo que consiste de las SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, y 15; y detectar la formación de complejos de anticuerpos-péptidos que comprende los polipéptidos aislado o los fragmentos antigénicos o variantes de los mismos, en donde la formación de los complejos es indicativa de la presencia de los anticuerpos para los epítopes de los antígenos de Mycobacterium tuberculosis en la muestra.
MX2019003288A 2016-09-22 2017-11-22 Proteínas de mycobacterium tuberculosis en pruebas diagnósticas y dispositivos para la detección y diagnóstico de la tuberculosis. MX2019003288A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662398213P 2016-09-22 2016-09-22
PCT/US2017/063154 WO2018068064A2 (en) 2016-09-22 2017-11-22 Mycobacterium tuberculosis proteins in diagnostic assays and devices for tuberculosis detection and diagnosis

Publications (1)

Publication Number Publication Date
MX2019003288A true MX2019003288A (es) 2019-11-05

Family

ID=61831255

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003288A MX2019003288A (es) 2016-09-22 2017-11-22 Proteínas de mycobacterium tuberculosis en pruebas diagnósticas y dispositivos para la detección y diagnóstico de la tuberculosis.

Country Status (7)

Country Link
US (1) US20190293645A1 (es)
EP (2) EP4257976A3 (es)
CN (1) CN110073215B (es)
BR (1) BR112019005732A2 (es)
CA (1) CA3059408A1 (es)
MX (1) MX2019003288A (es)
WO (1) WO2018068064A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113740529B (zh) * 2021-08-25 2023-05-26 华中农业大学 一种犬吉氏巴贝斯虫抗体乳胶凝集检测试剂盒及其制备方法和应用
WO2023028565A1 (en) * 2021-08-25 2023-03-02 Moon, Sung Woo Lateral flow assay by using carboxyl latex beads and biotin-polystreptavidin for the detection of covid-19 infection and diagnostic kit using the lateral flow assay

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2378051T3 (es) * 1995-09-01 2012-04-04 Corixa Corporation Compuestos y métodos para el diagnóstico de la tubercolosis.
US6458366B1 (en) * 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
GB9624456D0 (en) 1996-11-25 1997-01-15 Isis Innovation Assay method
US6982085B2 (en) * 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
US6291190B1 (en) * 1998-08-25 2001-09-18 The Board Of Trustees Of The Leland Stanford Junior University Molecular differences between species of the M. tuberculosis complex
ES2364520T3 (es) * 1998-08-25 2011-09-06 The Board Of Trustees Of The Leland Stanford Junior University Marco de lectura abierto rv2660c de m. tuberculosis y su utilización.
US20040018574A1 (en) * 1998-08-25 2004-01-29 Marcel Behr Molecular differences between species of the M. tuberculosis complex
CN1277843C (zh) * 2001-02-22 2006-10-04 巴斯德研究院 分枝杆菌比较基因组学作为鉴定分枝杆菌病的诊断、预防或治疗靶的工具
US20060046310A1 (en) 2004-08-25 2006-03-02 Zong-Li Xia Amplification method for solid phase immunoassays
BRPI0708865A8 (pt) * 2006-03-14 2019-01-22 Univ Oregon Health & Science métodos para produzir uma resposta imune à tuberculose
US7776341B2 (en) * 2006-08-10 2010-08-17 Colorado State University Research Foundation Biomarkers of tuberculosis that distinguish disease categories: use as serodiagnostic antigens
US7776618B2 (en) 2007-03-01 2010-08-17 Church & Dwight Co., Inc. Diagnostic detection device
CN102718848A (zh) * 2012-06-01 2012-10-10 上海交通大学 结核分枝杆菌Rv3120的重组蛋白、其制备方法及其在细胞免疫诊断中的应用

Also Published As

Publication number Publication date
WO2018068064A3 (en) 2018-06-28
WO2018068064A9 (en) 2018-05-31
CN110073215A (zh) 2019-07-30
BR112019005732A2 (pt) 2019-08-06
WO2018068064A2 (en) 2018-04-12
EP4257976A2 (en) 2023-10-11
EP3516394C0 (en) 2023-06-21
CA3059408A1 (en) 2018-04-12
CN110073215B (zh) 2024-04-30
EP4257976A3 (en) 2024-01-24
EP3516394B1 (en) 2023-06-21
EP3516394A2 (en) 2019-07-31
EP3516394A4 (en) 2020-09-02
US20190293645A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
AU2019283892A1 (en) Anti-human papillomavirus 16 E7 T cell receptors
BR112018070823A2 (pt) anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno, composição farmacêutica, produto de combinação, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, polipeptídeo, métodos para fabricar um anticorpo, in vitro ou ex vivo para determinar células positivas para sirpa, de diagnóstico e para prever a resposta de um sujeito, e, uso de um anticorpo anti-sirpa ou um fragmento de ligação a antígeno do mesmo ou um mimético de ligação a anticorpo e in vitro ou ex vivo de pelo menos um anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno.
JP2018042573A5 (es)
BR112017001818A2 (pt) receptores antigênicos quiméricos específicos para egfrviii para imunoterapia de câncer
SG10201906750XA (en) Assays for detecting the presence or amount of an anti-drug antibody
AR098126A1 (es) Anticuerpos anti-ly6e (locus e del complejo del antígeno 6 linfocítico), inmunoconjugados y métodos para usarlos
JP2016029056A5 (es)
JO3812B1 (ar) أجسام مضادة ترتبط بالمركب الترابطي البشري للموت المبرمج 1 (pd-l1)
MX2013014961A (es) Variantes anticuerpos y usos de las mismas.
JP2015533788A5 (es)
MX2015012824A (es) Antigenos recombinantes ns3 del vhc y mutantes de los mismos para la deteccion mejorada de anticuerpos.
MX353464B (es) Antigenos tpn47 de treponema pallidum, inmunoreactivos, solubles.
WO2015112558A3 (en) Peptides, devices, and methods for the detection of anaplasma antibodies
JP2017502253A5 (es)
MX2019002178A (es) Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
MX2019003288A (es) Proteínas de mycobacterium tuberculosis en pruebas diagnósticas y dispositivos para la detección y diagnóstico de la tuberculosis.
BR112016019739A2 (pt) novo anticorpo de anti-presepsina
WO2018085431A8 (en) Filamin a binding proteins and uses thereof
BR112018073660A2 (pt) anticorpos anti-fator ix pádua
Ronholm et al. Monoclonal antibodies recognizing the surface autolysin IspC of Listeria monocytogenes serotype 4b: epitope localization, kinetic characterization, and cross-reaction studies
JP2015529211A5 (es)
JP2017524689A5 (es)
WO2015128394A3 (en) Soluble and immunoreactive variants of htlv capsid antigen p24
MX2017005156A (es) Metodo para determinacion de anticuerpos de anti-farmaco contra anticuerpo de farmaco humano o humanizado de funcion efectora suprimida.
NZ700199A (en) Epsilon toxin epitopes from clostridium perfringens with reduced toxicity